A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks ... Therapeutics company Biogen (NASDAQ:BIIB) jumped 5.1%.

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

By Alimat Aliyeva Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it pla ...

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) ...

The rarity of SOD1-ALS means however that tofersen is unlikely to make big sales, even if it has a high price. With Biogen squeezed between competitive pressures to its current multiple sclerosis ...

Q1 2025 Earnings Call Transcript May 8, 2025 Royalty Pharma plc beats earnings expectations. Reported EPS is $1.06, expectations were $0.99. Operator: Ladies and gentlemen, thank you for standing by.

In-home care can be the most preferred option for patients with progressive diseases such as amyotrophic lateral sclerosis ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...